HC Wainwright Cuts Cardiff Oncology (NASDAQ:CRDF) Price Target to $13.00

Cardiff Oncology (NASDAQ:CRDF) had its price objective reduced by HC Wainwright from $14.00 to $13.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Craig Hallum initiated coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They set a “buy” rating and a $8.00 target price for the company.

Cardiff Oncology Stock Down 24.7 %

Shares of NASDAQ CRDF opened at $3.08 on Friday. Cardiff Oncology has a twelve month low of $0.94 and a twelve month high of $6.42. The firm has a fifty day simple moving average of $2.74 and a 200 day simple moving average of $2.76. The company has a market capitalization of $143.37 million, a PE ratio of -3.28 and a beta of 1.93.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 70.45% and a negative net margin of 6,238.17%. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.12 million. During the same period in the prior year, the business earned ($0.25) EPS. As a group, equities analysts expect that Cardiff Oncology will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of CRDF. Point72 DIFC Ltd bought a new stake in Cardiff Oncology in the second quarter valued at $27,000. Ground Swell Capital LLC bought a new stake in Cardiff Oncology in the second quarter valued at $38,000. Dimensional Fund Advisors LP increased its stake in Cardiff Oncology by 34.4% in the second quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock valued at $42,000 after purchasing an additional 4,892 shares in the last quarter. SG Americas Securities LLC bought a new stake in Cardiff Oncology in the third quarter valued at $64,000. Finally, Invst LLC bought a new stake in shares of Cardiff Oncology during the second quarter worth about $74,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.